Randomized Controlled Trial of Mycophenolate Mofetil Versus Steroid Therapy in Alcoholic Hepatitis
Key facts
- Who runs it
- Institute of Liver and Biliary Sciences, India
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 60 people, planned
- Started
- 20 Jan 2025
- Planned end
- 31 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Mycophenolate Mofetil
- Prednisone
- Record updated
- 23 January 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adults aged 18-70 years
- Diagnosis of Alcoholic hepatitis based on NIAAA criteria
- MELD 20-35
- Willing to follow up
Who cannot take part
- Patients with contraindications to steroids
- Patients who are on current treatment with prednisone and/or immunosuppressive me
- Patients with hepatic/ extra hepatic malignancies
- Patient who have severe extra hepatic organ failure
- Patients who are HBsAg +, HIV+
- Patients who are critically ill and are admitted to the ICU
- If female of childbearing potential: known pregnancy, or unwilling to practice anticontraceptive measures
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Patients with acute alcoholic hepatitis will be identified based on national institute on alcohol abuse and alcoholism (NIAAA) will be identified, MELD score will be calculated, patents with MELD score between 20-35 will be randomized to two groups. Group A (intervention arm) will be receiving Mycofenolate mofetil at a dose of 750 mg twice daily and group B will be receiving steroid as per existing guidelines in a dose of 40 mg per day. Both the groups will be followed up for 90 days with assessment done at 4th, 7th and 28th day. Any significant event in addition will also be noted. Patients in group A will be also be monitored for development of complications like cytopenia due to Mycofenolate mofetil and infections will be monitored in both groups. Steroids will be stopped in the non-responders in group B based on Lille score at 4th and 7th day. The outcome variables of interest and to be measured are survival at 28 days and 90 days, clinical outcomes, including hospitalization and liver related outcomes.
The 2 groups in the trial
- mycophenolate mofetilTreatment being tested
Intervention arm in the study will receive MMF at a dose of 750 mg twice daily for a period of 28 days.
- Steroid prednisoloneExisting treatment, for comparison
steroid at a dose of 40 mg for 28 days.
Treatment: Prednisone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Fit questions
- Built from NCT06789315, who can take part
- Record updated
- 23 January 2025